- Home
- XRTX vs INM Comparison
XRTX vs INM Comparison
Compare XRTX & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XRTX
- INM
- Stock Information
- Founded
- XRTX 2011
- INM 1981
- Country
- XRTX Canada
- INM Canada
- Employees
- XRTX N/A
- INM N/A
- Industry
- XRTX Pharmaceuticals and Biotechnology
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- XRTX Health Care
- INM Health Care
- Exchange
- XRTX Nasdaq
- INM Nasdaq
- Market Cap
- XRTX 3.0M
- INM 3.2M
- IPO Year
- XRTX N/A
- INM N/A
- Fundamental
- Price
- XRTX $1.08
- INM $3.00
- Analyst Decision
- XRTX
- INM
- Analyst Count
- XRTX 0
- INM 0
- Target Price
- XRTX N/A
- INM N/A
- AVG Volume (30 Days)
- XRTX 44.3K
- INM 56.6K
- Earning Date
- XRTX 05-16-2025
- INM 05-13-2025
- Dividend Yield
- XRTX N/A
- INM N/A
- EPS Growth
- XRTX N/A
- INM N/A
- EPS
- XRTX N/A
- INM N/A
- Revenue
- XRTX N/A
- INM $4,832,013.00
- Revenue This Year
- XRTX N/A
- INM N/A
- Revenue Next Year
- XRTX N/A
- INM N/A
- P/E Ratio
- XRTX N/A
- INM N/A
- Revenue Growth
- XRTX N/A
- INM N/A
- 52 Week Low
- XRTX $0.80
- INM $1.72
- 52 Week High
- XRTX $3.24
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- XRTX 59.65
- INM 62.76
- Support Level
- XRTX $0.82
- INM $2.56
- Resistance Level
- XRTX $1.13
- INM $3.05
- Average True Range (ATR)
- XRTX 0.10
- INM 0.27
- MACD
- XRTX 0.03
- INM 0.09
- Stochastic Oscillator
- XRTX 71.65
- INM 92.98
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.